Pharmalot… Pharmalittle… Good Morning

Good morning, everyone, and how are you today? We hope the weekend was relaxing and invigorating, because now, the familiar routine of deadlines and meetings and all manner of busywork has returned. What can you do? So, to cope, we are brewing that needed cup of stimulation. Feel free to join us. After all, a pick-me-up is not a bad thing. Meanwhile, here are some tidbits to get you going. Hope your day goes well and you conquer the world… California Legislator Vows To Curb Reckless Prescribing (Los Angeles Times) Patients Are Rarely Told About Medication Errors: Study (Reuters) Job Cuts Feared At AstraZeneca R&D Hub In UK (Manchester Evening News) EU Expands Approval For J&J Zytiga Prostate Cancer Med (Pharma Times) Former Abbott Unit Issues Second Synthroid Recall (Dow Jones) Japan Allows Online Sales Of OTC Drugs (Bloomberg News) Life In A NJ Town After Roche Leaves (Star-Ledger of NJ) Flu Gives Reckitt And J&J A Needed Shot (Ad Age) GSK Files For US Approval Of New Diabetes Drug (Reuters) J&J Mesh Failure Rate Topped 20 Percent, Jury Told (Bloomberg News) EMA Says No Risk With Combined Contraceptives (Pharma Times) Singapore Court Allows Novartis To Modify Diovan Patent (BT Premium) EDITOR’S NOTE: Please check this post for updates morning coffee pic thx to chichacha on flickr
Source: Pharmalot - Category: Pharma Commentators Authors: Tags: Uncategorized Abbott Laboratories Abbvie AstraZeneca Contraceptives Diovan EMA Flu JJ Johnson & Johnson Layoffs Medication Errors Mesh Implants Novartis OTC Drugs Over-the-Counter Drugs Patents Prescription Painkillers Source Type: blogs